Integrated Medical Professionals, PLLC (IMP)

Background

Integrated Medical Professionals, PLLC (IMP) is a multi-specialty physician group operating in the greater New York Metropolitan area. Established in 2006, IMP's mission is to provide patients with the highest level of care, emphasizing clinical outcomes and patient satisfaction. The organization integrates surgical specialists with physicians offering diagnostic and therapeutic services, enhancing the quality and efficiency of medical care. IMP's vision is to be the preferred provider by equipping physicians with advanced technological and management tools, allowing them to focus on patient care while administrative functions are centralized.

Key Strategic Focus

IMP specializes in urology, radiation oncology, and pathology services. The group comprises over 100 board-certified physicians across more than 50 locations, including divisions such as Advanced Urology Centers of New York (AUCNY) and Advanced Radiation Centers of New York (ARC). IMP's strategic objectives include:

• Forward Integration Model: Combining surgical specialists with diagnostic and therapeutic physicians to streamline patient care.

• Technological Advancement: Utilizing cutting-edge technologies like Image-Guided Radiation Therapy (IGRT) and Rapid Arc Rotational Arc Therapy to improve treatment outcomes.

• Geographic Accessibility: Ensuring that patients within the New York metro area are within eight miles of an IMP facility, enhancing convenience and access to care.

Financials and Funding

IMP operates as a privately held entity and does not publicly disclose detailed financial information. However, estimates suggest:

• Annual Revenue: Approximately $60.9 million, with revenue per employee around $297,000.

• Employee Count: Approximately 205 employees, reflecting a 7% growth in the past year.

These figures indicate a robust financial position and a commitment to expanding services and capabilities.

Pipeline Development

IMP is actively involved in clinical research and development, notably:

• Erectile Dysfunction Study: Initiated a Phase 2 clinical study of Bremelanotide co-administered with a PDE5 inhibitor for treating erectile dysfunction. Dr. Jed Kaminetsky, Director of Research at IMP, leads this study, aiming to address the increasing prevalence of erectile dysfunction and improve patient outcomes.

Technological Platform and Innovation

IMP distinguishes itself through several proprietary technologies and methodologies:

• Advanced Radiation Technologies: Pioneering the use of IGRT and Rapid Arc Rotational Arc Therapy, enhancing precision in radiation oncology treatments.

• DNA Verification in Pathology: Implementing DNA verification in diagnostic pathology labs, ensuring diagnostic accuracy and reliability.

• Clinical Affiliation with Mount Sinai Hospital: Collaborating to provide state-of-the-art screening, assessment, and treatment for complex urologic conditions, improving access to advanced radiation oncology services.

Leadership Team

IMP's leadership comprises experienced professionals dedicated to advancing the organization's mission:

• Deepak A. Kapoor, MD: Chairman and CEO, overseeing strategic direction and operations.

• W. Price Dunaway: Chief Operating Officer, managing daily operations and organizational efficiency.

• Kathleen L. Latino, MD, FACS, CHC: Chief Medical Officer, guiding clinical practices and quality standards.

• Marc A. Schumer, MD, FACS: Associate Medical Director, supporting medical leadership and innovation.

• Shawn H. Zimberg, MD: Director of Radiation Oncology Services, leading radiation oncology initiatives.

• Ann E. Anderson, MD, FCAP: Director of Pathology, overseeing pathology services and advancements.

• Karen Hohlman: Vice President of Operations, managing operational strategies and implementation.

• Elizabeth Marano, MSN, RN: Director of Operations, focusing on operational excellence and patient care.

• Randi Pincus: Director of Marketing, leading marketing strategies and outreach.

• Jonathan Anderson: Director of Laboratory Operations, ensuring laboratory quality and efficiency.

• Daniel D’Amico: Director of Information Technology Services, overseeing IT infrastructure and innovation.

Leadership Changes

As of the latest available information, there have been no recent significant changes or appointments within IMP's leadership team.

Competitor Profile

Market Insights and Dynamics

The healthcare industry, particularly in multi-specialty physician groups, is experiencing growth driven by:

• Increased Demand for Specialized Care: Rising prevalence of chronic diseases necessitates specialized medical services.

• Technological Advancements: Innovations in medical technology enhance treatment options and patient outcomes.

• Consolidation Trends: Physician groups are merging to improve service offerings and operational efficiencies.

Competitor Analysis

IMP operates in a competitive landscape with several notable entities:

• Saad Healthcare: Provides home healthcare services, focusing on personalized patient care.

• Savannah Court: Offers assisted living and memory care services, emphasizing senior care.

• Sonora Behavioral Health Hospital: Specializes in behavioral health services, addressing mental health needs.

These competitors focus on different aspects of healthcare, highlighting IMP's unique position in offering integrated urology, radiation oncology, and pathology services.

Strategic Collaborations and Partnerships

IMP has established significant collaborations to enhance its service offerings:

• Clinical Affiliation with Mount Sinai Hospital: This partnership facilitates access to advanced treatments for complex urologic conditions and radiation oncology services, combining academic excellence with community-based care.

• Affiliation with Solaris Health: As an affiliate, IMP benefits from a national healthcare platform, supporting growth and innovation in urological and specialty services.

Operational Insights

IMP's strategic considerations include:

• Forward Integration Model: Streamlining patient care by integrating surgical specialists with diagnostic and therapeutic services.

• Technological Investment: Committing to advanced technologies to improve treatment precision and patient outcomes.

• Geographic Expansion: Ensuring widespread accessibility to services within the New York metro area.

These strategies position IMP as a leader in providing comprehensive, high-quality medical care.

Strategic Opportunities and Future Directions

IMP's future roadmap focuses on:

• Expanding Service Offerings: Introducing new specialties and services to meet evolving patient needs.

• Enhancing Technological Capabilities: Investing in emerging medical technologies to maintain a competitive edge.

• Strengthening Partnerships: Building on existing collaborations and exploring new alliances to enhance service delivery and innovation.

By leveraging its current strengths and strategic initiatives, IMP aims to continue its growth and leadership in the healthcare industry.

Contact Information

For more information, visit IMP's official website.